Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: EYLEA Clear all

Conditions: Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions: ziv-aflibercept, leucovorin calcium, fluorouracil, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Neovascular Age-related Macular Degeneration
Interventions: Intravitreal Aflibercept Injection 2mg; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 115
States / cities: Birmingham (2 Locations), Alabama • Phoenix (2 Locations), Arizona • Tucson (2 Locations), Arizona + 112 more

Conditions: Wet Age-related Macular Degeneration
Interventions: Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept; Drug
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 50 Years and older
Enrollment: 667 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 71
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 66 more

Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Neovascular (Wet) Age-related Macular Degeneration (AMD)
Interventions: Aflibercept (2.0 mg); Biological
Lead sponsor: Exegenesis Bio; Industry
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Reno, Nevada • Erie, Pennsylvania

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: OTX-TKI (axitinib implant), Aflibercept; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 97
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 81 more

Conditions: Fibrovascular Pigment Epithelial Detachment
Interventions: Aflibercept; Drug
Lead sponsor: Vitreous -Retina- Macula Consultants of New York; Other
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Wet Age Related Macular Degeneration, wAMD
Interventions: EYP-1901, Aflibercept (2.0 mg); Drug
Lead sponsor: EyePoint Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 76
States / cities: Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 70 more

Conditions: Macular Degeneration
Interventions: NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks; Drug
Lead sponsor: Neurotech Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 32
States / cities: Phoenix, Arizona • Beverly Hills, California • Irvine, California + 28 more

Conditions: Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions: THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3, THR-149 0.13mg, THR-149 0.13mg + aflibercept 2mg, aflibercept 2mg + THR-149 0.13mg, Aflibercept 2mg; Drug
Lead sponsor: Oxurion; Industry
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 41
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 32 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: CLS-AX, Anti-VEGF; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 11
States / cities: Phoenix, Arizona • Bakersfield, California • Mountain View, California + 8 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: SOK583A1 (40 mg/mL), Eylea EU (40 mg/mL); Biological
Lead sponsor: Sandoz; Industry
Eligibility: 50 Years and older
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 28
States / cities: Phoenix, Arizona • Arcadia, California • Campbell, California + 25 more

Conditions: Exudative Macular Degeneration
Interventions: Aflibercept; Drug
Lead sponsor: Rishi Singh; Other
Eligibility: 50 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metastatic Colorectal Cancer
Interventions: Capecitabine and aflibercept; Drug
Lead sponsor: John Strickler, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Durham, North Carolina • Norfolk, Virginia

Conditions: Macular Degeneration
Interventions: ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321); Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 1,217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 176
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more

Conditions: Diabetic Retinopathy, Macular Edema
Interventions: MK-8748, Aflibercept; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 37
States / cities: Gilbert, Arizona • Glendale, California • Sacramento, California + 33 more

Conditions: Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions: ADVM-022; Biological
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 11
States / cities: Bakersfield, California • Beverly Hills, California • Golden, Colorado + 8 more

Conditions: Polypoidal Choroidal Vasculopathy
Interventions: Intravitreal aflibercept injection 2.0mg; Drug
Lead sponsor: Gregg T. Kokame, MD; Other
Eligibility: 25 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: ‘Aiea, Hawaii

Conditions: Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Solid Neoplasm
Interventions: Sapanisertib, Ziv-Aflibercept; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Non Small Cell Lung
Interventions: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo, Docetaxel (Taxotere®), Dexamethasone (pre- and post-medication for docetaxel); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 913 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions: Aflibercept 8 mg; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 53
States / cities: Arcadia, California • Bakersfield, California • Beverly Hills, California + 48 more

Conditions: Diabetic Macular Edema, Cataract
Interventions: Aflibercept injected Pre- and Post-operatively, Aflibercept injected intraoperatively; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Cancer
Interventions: aflibercept (AVE0005), placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions: THR-687 dose level 1, THR-687 dose level 2, THR-687 selected dose level, Aflibercept; Drug
Lead sponsor: Oxurion; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 18
States / cities: Huntington Beach, California • Pasadena, California • Sacramento, California + 15 more

Conditions: Diabetic Macular Edema
Interventions: Brolucizumab, Aflibercept; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 39
States / cities: Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 33 more

Search by objective public record fields.

Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer

Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration

Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept

Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

ADVM-022 Intravitreal Gene Therapy for Wet AMD

Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

Cataract DME - Peri vs. Intraop

A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients

A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema